Aegerion endocrine/metabolic news

Aegerion will reduce global staff by about 77 (25%) to about 230 to cut costs as its hypercholesterolemia treatment Juxtapid lomitapide faces increased competition in the U.S. The company said in January it expected Juxtapid sales to be $37.5-$39.5 million in 4Q15 and $211-$213 million for the year. In November, Aegerion said switches to PCSK9 inhibitors were higher than expected. Aegerion expects to complete the cuts, which will include positions in all major departments, next quarter. Juxtapid is a small molecule microsomal triglyceride transfer protein ( MTTP; MTP) inhibitor. ...